SR-16234, a Novel Selective Estrogen Receptor Modulator for Pain Symptoms with Endometriosis: An Open-label Clinical Trial by Harada, Tasuku et al.
227
Yonago Acta Medica 2017;60:227–233  doi: 10.24563/yam.2017.12.003 Original Article
Corresponding author: Tasuku Harada, MD, PhD
tasuku@med.tottori-u.ac.jp
Received 2017 August 31
Accepted 2017 November 9 
Abbreviations: AE, adverse effect; BMD, bone mineral density; E2, 
estradiol; ER, estrogen receptor; GnRH; gonadotropin releasing 
hormone; GPR30, G protein coupled estrogen receptor; SERM, se-
lective estrogen receptor modulator; VAS, visual analogue scale
SR-16234, a Novel Selective Estrogen Receptor Modulator for Pain Symptoms 
with Endometriosis: An Open-label Clinical Trial
Tasuku Harada,* Ikuko Ohta,† Yusuke Endo,‡ Hiroshi Sunada,‡ Hisashi Noma§ and Fuminori Taniguchi* 
*Department of Obstetrics and Gynecology, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan, †De-
partment of Obstetrics and Gynecology, Kurashiki Heisei Hospital, Kurashiki 710-0826, Japan, ‡Advanced Medicine, Innovation and 
Clinical Research Center, Tottori University Hospital, Yonago 683-8504, Japan, and §Department of Data Science, The Institute of Sta-
tistical Mathematics, Tokyo 190-8562, Japan
ABSTRACT
Background    SR-16234 is a selective estrogen receptor 
modulator (SERM) structurally different from approved 
SERM and has been reported to have estrogen receptor 
(ER) α antagonistic activity and strong affinity with 
a weak partial agonistic activity to ERβ receptor. SR-
16234 showed strong inhibitory effects on transplanted 
endometrial cysts in the endometriosis model of rat and 
mouse. In this clinical trial, efficacy and safety of SR-
16234 have been evaluated in endometriosis patients.
Methods    This trial was an open-label single arm clini-
cal trial. Ten patients with dysmenorrhea and pelvic pain 
associated with endometriosis and adenomyosis were 
enrolled in this trial, and received 40 mg of SR-16234 
once daily for 12 weeks. The primary endpoint was the 
visual analogue scale (VAS) of pelvic pain. The sec-
ondary endpoints included dysmenorrhea score, pelvic 
pain score, objective observations (stiffness of Douglas’ 
pouch, limitation of uterine movement, size of ovarian 
chocolate cysts, thickness of endometrium, and serum 
CA125 concentration) and safety. 
Results    After oral administration of SR-16234 40 mg 
for 12 weeks, there were statistically significant decreas-
es in pelvic pain VAS, total pelvic pain score, total dys-
menorrhea score, stiffness of Douglas’ pouch, limitation 
of uterine movement compared with the baseline values. 
Conclusion    The present trial suggested that a selective 
estrogen receptor modulator could be used for treatment 
of pain associated with endometriosis for the first time.
Key words    estrogen receptor; endometriosis; selective 
estrogen receptor modulator; pelvic pain; open clinical 
trial 
Endometriosis is a chronic and recurrent gynecological 
disease affecting 10% of reproductive age women. As it 
has been considered as an estrogen dependent disease, 
modalities to suppress endogenous estrogen levels have 
been widely utilized. Gonadotropin releasing hormone 
(GnRH) agonist has been a representative agent which 
can induce hypoestrogenic state and reduce pain symp-
toms and endometriosis lesions.1 In addition, efficacy of 
aromatase inhibitors has been reported and is now used 
as an off label indication in menopausal patients.2, 3 
 Estrogen receptor antagonist or so called SERM in-
cluding tamoxifen and fluvestrant have already established 
clinical efficacy for estrogen receptor positive breast can-
cer. Several SERMs have been evaluated in animal models 
of endometriosis, including raloxifene,4, 5 LY-2066948,6 
TZE-53237 and bazedoxifene,8 and efficacies on the re-
gression of endometriotic lesions have been reported. So 
far, however, efficacy of SERM has not been reported in 
endometriosis patients. 
 Tamoxifen, the first generation of SERM for 
treatment of breast cancer, induced endometriosis in 
post-menopausal breast cancer patients.9, 10 Raloxifene 
used for postoperative patients with endometriosis 
showed a significantly shortened time for the return of 
chronic pelvic pain.11 Partial agonistic activity of those 
SERMs to ERα is suggested as a potential reason to be 
detrimental for endometriosis. 
 SR-16234 is a SERM structurally different from 
the SERMs mentioned above and has been reported to 
have ERα antagonistic activity and strong affinity with a 
weak partial agonistic activity to ERβ receptor.12, 13 Effi-
cacy of this compound for breast cancer has been evalu-
ated.14,15 We have confirmed inhibitory effects on trans-
planted endometrial cysts in the endometriosis model of 
rat and mouse (unpublished data). In this clinical trial, 
efficacy and safety of SR-16234 have been evaluated in 
endometriosis patients.
MATERIALS AND METHODS
Patient Selection
Patient inclusion criteria included women of 20 years 
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and older with regular menstrual cycle who have symp-
tomatic endometriosis or adenomyosis. Usage of proges-
tins, oral contraceptives, GnRH agonists, testosterone 
derivatives, FSH antagonist, aromatase inhibitors, and 
other drugs that might effect the secretion of sex hor-
mones, and fixation with alcohol through the vagina, 
laparotomy, laparoscopic therapy or examinations were 
prohibited throughout the 12 weeks of the period from 
initiation to completion of SR-16234 administration. All 
patients provided written, informed consent prior to trial 
initiation.
Study Design
This was an open-label trial in 10 patients with endome-
triosis performed at two investigational sites (a university 
hospital, a general hospital) in Japan. Patients received 
SR-16234 40mg once daily for 12 weeks, and then fol-
low-up was performed for 4 weeks. Treatment began on 
the second day of the menstrual cycle. SR-16234 was 
prepared as a 40mg capsule. The use of analgesic agents 
was allowed, but other hormonal treatments for pain or 
vaginal bleeding were prohibited. 
 The primary endpoint was the VAS of pelvic pain, 
the secondary endpoints included dysmenorrhea score, 
Table 1. Pelvic pain score: Grading and scoring of 
symptoms and requirement of analgesics
Grade Symptom Score
Pelvic pain
No None 0
Slight
Some disturbances to daily 
work (school work/house 
keeping)
1
Moderate
Disturbances to daily work 
(school work/house keeping) 
or need rest in bed
2
Severe Staying in bed unable to work/to do house keeping 3
Use of analgesic
No No usage of analgesics 0
Slight
Usage of analgesics in one 
day due to pelvic pain other 
than during menstruation 
from the time of menstrua-
tion one month previous
1
Moderate
Usage of analgesics for 2–6 
days due to pelvic pain other 
than during menstruation 
from the time of menstrua-
tion of one month previous
2
Severe
Usage of analgesics for 
more than 7 days due to 
pelvic pain other than during 
menstruation from the time 
of menstruation one month 
previous
3
Total pelvic pain score is the sum of 1) pelvic pain score and 2) 
use of analgesic score.
 
Table 2. Dysmenorrhea score: Grading and scoring of 
symptoms and requirement of analgesics
Grade Symptom Score
Dysmenorrhea
No None 0
Slight
Some disturbances to daily 
work (school work/house 
keeping)
1
Moderate
Disturbances to daily work 
(school work/house keeping) 
or need rest in bed
2
Severe Staying in bed unable to work/to do house keeping 3
Use of analgesic
No No usage of analgesics 0
Slight Usage of analgesics in one day at menstruation 1
Moderate Usage of analgesics for 2–6 days at menstruation 2
Severe Usage of analgesics for more than 7 days at menstruation 3
Total dysmenorrhea score is the sum of 1) dysmenorrhea score 
and 2) use of analgesic score.
 
pelvic pain score, objective observations (stiffness of 
Douglas’ pouch, limitation of uterine movement, size of 
ovarian chocolate cysts, and thickness of endometrium) 
and safety. 
 The final protocol was approved by the ethics re-
view committees of each hospital. This clinical trial 
was registered with the UMIN Clinical Trials Registry 
(UMIN000019193), and was conducted in accordance 
with the ethical principles established in the Declaration 
of Helsinki and consistent with Ethical Guidelines for 
Clinical Research.
Patient Monitoring 
During the 6 weeks of screening period before initiating 
administration, each patient underwent a pre-recruit-
ment evaluation, consisting of a general medical and 
gynecologic history, physical and pelvic examination, 
clinical evaluation of signs and symptoms, VAS of pel-
vic pain, pelvic pain score (Table 1), dysmenorrhea score 
(Table 2), use of analgesics, objective observations (stiff-
ness of Douglas’ pouch, limitation of uterine movement 
(Table 3), size of ovarian chocolate cysts, and thickness 
of endometrium), clinical laboratory assessments, vital 
signs and 12 lead ECG. Laboratory assessments include 
hematology test (white blood cells, platelet, red blood 
cells, hemoglobin, and hematocrit), biochemical test 
(total protein, albumin, GOT, GPT, r-GTP, Al-P, LDH, 
total bilirubin, total cholesterol, high density lipopro-
tein-cholesterol, TG, BUN, Creatinine, Ca, Fe, P, Na, 
K, and Cl) and urinalysis. At this period, eligibility 
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Table 3. Evaluation method of stiffness of Douglas’ 
pouch and limitation of uterine movement
Severity
Stiffness of 
Douglas’ pouch
0 None: no finding
1
Very slight: the degree to which the 
induration is smaller than the size of 
the little finger tip 
2
Slight: the degree to which the 
induration is about the same size as 
the little finger tip
3 Moderate: intermediate degree between “Slight” and “Severe”
4 Severe: complete closure of Doug-las’ pouch and no resilience
Limitation of 
uterine move-
ment
0 None: no finding
1
Very slight: the degree to which 
there is a slight, hardly recognizable 
limitation of uterine flexibility
2 Slight: the degree to which there is a clear limitation of uterine flexibility
3
Moderate: the degree to which there 
is a definite, strong, yet not complete 
limitation of uterine flexibility
4 Severe: complete limitation of uter-ine movement flexibility
for enrollment into the trial was determined, and SR-
16234 was prescribed. VAS of pelvic pain, pelvic pain 
score, dysmenorrhea score, use of analgesics, objective 
observations (stiffness of Douglas’ pouch, limitation of 
uterine movement, size of ovarian chocolate cysts, and 
thickness of endometrium) were evaluated at 4, 8 and 12 
weeks. Safety assessments were performed throughout 
the trial. 
Statistical Analysis
The mean changes of the VAS of pelvic pain, total pelvic 
pain score, total dysmenorrhea score, pelvic pain score, 
dysmenorrhea score, score of analgesic use for pelvic 
pain, score of analgesic use for dysmenorrhea, stiffness 
of Douglas’ pouch, limitation of uterine flexibility and 
thickness of endometrium from baseline were evaluated 
at 4, 8, 12 weeks after administration of SR-16234. 
 The changes of the outcome variables were ana-
lyzed with the paired t-test. All of the statistical tests 
were 2-sided with an α level of 0.05 and were performed 
using SAS version 9.4 (SAS Institute, Cary, NC).
RESULTS
Patient Characteristics
Ten patients were enrolled in this clinical trial and all 
patients completed the trial until follow-up period. The 
Table 4. Demographic data of the patients
Number of patients
Endometriosis 9
Adenomyosis 1
Age (Years)
Average 39.6
SD 3.66
Minimum 34
Maximum 46
Age of the first menstruation (Years)
Average 12.9
SD 3.7
Minimum 11
Maximum 23
Present menstruation
Yes 10 (100%)
Menstruation cycle
Normal 10 (100%)
Menstrual cycle (Days)
Average 29.4
SD 4.14
Duration of menstruation (Days)
Average 6.5
SD 1.18
Volume of menstruation
Small 0
Moderate 3 (30%)
Large 7 (70%)
Number of pregnancy
0 2 (20%)
1 2 (20%)
2 5 (50%)
3 1 (10%)
Number of delivery
0 4 (40%)
1 1 (10%)
2 5 (50%)
Method of diagnosis 
Histological 0
Clinical 10 (100%)
Surgery
Yes 1 (10%)
No 9 (90%)
Prior therapy
Yes 5 (50%)
No 5 (50%)
Complication
Yes 1 (10%)
No 9 (90%)
demographic data of those patients are summarized in 
Table 4.
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Changes in pelvic pain VAS
Changes in the mean pelvic pain VAS as the primary 
endpoint at baseline and 4, 8, 12 weeks after initiation 
of treatment of SR-16234 are shown in Fig. 1. VAS of 
pelvic pain signifi cantly decreased at 4, 8 and 12 weeks 
compared with the baseline.
Changes in total pelvic pain score and total dys-
menorrhea score
Changes in the mean total pelvic pain score and total 
dysmenorrhea score at baseline and 4, 8, 12 weeks 
after initiation of treatment of SR-16234 are shown in 
Fig. 2, 3, respectively. Total pelvic pain score and total 
dysmenorrhea score signifi cantly decreased throughout 
the treatment period compared with the baseline. Pelvic 
pain score, score of analgesic use for pelvic pain, total 
dysmenorrhea score and score of analgesic use for dys-
menorrhea that consist of total score also signifi cantly 
decreased throughout the treatment period compared 
with the baseline (Data not shown).
Effects of SR-16234 on stiffness of Douglas’ 
pouch, limitation of uterine movement, endometri-
um thickness, and size of chocolate cyst
Douglas’ pouch stiffness and limitation of uterine 
movement were analyzed in nine patients, and the mean 
severity of Douglas’ pouch stiffness and limitation of 
uterine movement decreased after treatment. (3.44 and 
3.44 at baseline, 2.44 and 2.55 at 12 weeks, respective-
ly). Endometrial thickness was evaluated in 8 patients, 
and mean endometrial thickness at 12 weeks (6.87 mm) 
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Fig. 1. Effects of SR-16234 on pelvic pain VAS in endometriosis 
patients. Differences in the changes of VAS were analyzed with 
the paired t-test. Data are represented as mean ± standard devia-
tion. (n = 10, ** P < 0.01, ***P < 0.001)
VAS, visual analogue scale.
Fig. 2. Effects of SR-16234 on total pelvic pain score in endome-
triosis patients. Differences in the changes of score were analyzed 
with the paired t-test. Data are represented as mean ± standard 
deviation. (n = 10, ** P < 0.01, *** P < 0.001)
Fig. 3. Effects of SR-16234 on total dysmenorrhea score in en-
dometriosis patients. Differences in the changes of score were 
analyzed with the paired t-test. Data are represented as mean ± 
standard deviation. (n = 10, *** P < 0.001)
was less than that of baseline (9.75 mm). Effect of SR-
16234 administration on the size of chocolate cyst was 
evaluated in one patient. A chocolate cyst with volume 
of 13,305 mm3 was decreased to 4,521 mm3 at 4 weeks 
and 1,914 mm3 at 8 weeks, respectively and disappeared 
at 12 weeks.
Adverse events
Three patients reported adverse events in this clinical 
trial including contusion of the right leg and hemorrhage 
subcutaneous of the right leg (1), nausea (1) and com-
mon wart (1) but none of these conditions were found to 
have any relation to SR-16234 usage. No serious adverse 
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events were reported in this trial. There were no clinical-
ly signifi cant changes in clinical laboratory assessments 
(hematology, biochemical and urinalysis), vital signs and 
12 lead ECG (data not shown).
DISCUSSION
Endometriosis is often manifested by pain symptoms, 
such as dysmenorrhea, pelvic pain, and dyspareunia. 
Current therapeutic options include conservative surgery 
and medical treatment with oral contraceptives, GnRH 
agonist, danazol, and progestins.16–18 
 Surgical therapy for endometriosis continues to be 
the primary therapeutic measure and a Cochrane me-
ta-analysis of 5 randomized controlled studies evaluating 
laparoscopic treatment of endometriosis compared with 
diagnostic laparoscopy without treatment reported that 
pain was signifi cantly improved in the treatment group. 
However, recurrence rate after surgical therapy is high 
and may be associated with significant complication 
rates. In addition, in the case of ovarian endometriosis, 
there is concern about the risk of ovarian damage and 
impaired ovarian reserve.19 
 Medical treatment of pain associated with endome-
triosis is generally effective with little difference in effi -
cacy observed among the different types of agents used; 
however, the adverse event profi les of the various drug 
regimens markedly differ.1, 3, 20, 21 
 As endometriosis is considered an estrogen depen-
dent disease, induction of a hypoestrogenic condition is 
one major active mechanism using established medical 
agents. GnRH agonist is one representative inducer of 
the hypoestrogenic condition. Although strong effi cacy 
of GnRH agonist is well known for controlling pain 
symptoms of endometriosis, hypoestrogenic side effects 
including hot fl ushes, vaginal dryness, emotional labil-
ity, loss of libido, and signifi cant loss in bone mineral 
density (BMD) are problematic. Reduction of BMD may 
not be recovered until a few years after completion of 
the treatment. Due to these concerns, administration pe-
riod of GnRH agonist is basically limited to less than 6 
months.20, 21
 Endometriotic implants express a high level of 
aromatase and generate their own estrogen, which can 
maintain their viability and growth.22 As aromatase 
inhibitors inhibit local estrogen production in endome-
triotic implants, its effi cacy for endometriosis has been 
evaluated.23 A systematic review of eight studies showed 
that aromatase inhibitors combined with progestogens, 
oral contraceptives, or GnRH agonists had reduced 
mean pain scores and lesion size and improved QOL. 
However, monotherapy with aromatase inhibitor admin-
istered to reproductive age women will cause increased 
FSH levels and subsequent superovulation which may 
result in ovarian cyst development due to the initial FSH 
rise.24 Other concerns about prolonged aromatase in-
hibitor therapy are many, including associated bone loss 
secondary to hypoestrogenism.24 
 Due to the estrogen dependent nature of endome-
triosis, SERMs have been proposed for the treatment 
of endometriosis.25 However, no SERMs have been re-
ported to be effective in the treatment of endometriosis.3 
SERM is an acronymic term for a group of drugs that 
selectively modulate estrogen receptor. Tamoxifen is a 
fi rst generation SERM used for the treatment of breast 
cancer. Usage of tamoxifen as an alternative modality 
in the treatment of endometriosis, especially for women 
desiring to conceive, was expected. However, after wide 
spread use of tamoxifen for breast cancer, occurrences of 
endometriosis was reported in postmenopausal patients 
who had been taking tamoxifen for treatment of breast 
cancer. And it had been suggested that long term tamox-
ifen users are more likely to have endometrial hyperpla-
sia, endometrial polyps, and/or endometrial cancer.9, 10
 As these effects of tamoxifen were considered to be 
derived from its estrogen receptor agonistic activity, oth-
er SERMs that have more selective estrogenic activity 
were evaluated. Raloxifene has been used for the treat-
ment of postmenopausal osteoporosis. In a randomized 
clinical trial in biopsy proven endometriosis with chron-
ic pelvic pain, the raloxifene group experienced signif-
icant pain and had secondary surgery statistically sig-
nifi cantly sooner than the placebo group. This truncated 
trial concluded that raloxifene statistically signifi cantly 
shortened the time of return to chronic pelvic pain.11
 The mechanism of failure of raloxifene was not 
well explained in that publication. It may depend on the 
agonistic activity of raloxifene to the G protein coupled 
estrogen receptor (GPR30). While many effects of estro-
gen are mediated by its action at its nuclear estrogen re-
ceptors, ERα and ERβ, novel estrogen receptor GPR30 
and peripheral administration of GPR30 agonists or 
estradiol (E2) produces mechanical hyperalgesia within 
minutes after injection.26 Locally injected raloxifene 
close to the endometrial implant in the rat model of en-
dometriosis also induced mechanical hyperalgesia at a 
comparable dose with E2.4 
 Bazedoxifene reduced the size of endometrial le-
sions with experimental evidence of an antiproliferative 
effect in mouse and rat models.8 In addition bazedox-
ifene was shown to decrease proliferating cell nuclear 
antigen and estrogen receptor expression in the endome-
trium of treated animals compared with controls. How-
ever, the effectiveness of bazedoxifene on endometriosis 
in humans has not been published. 
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 The data of the present clinical trial suggests that 
SR-16234 may alleviate dysmenorrhea and pelvic pain 
of endometriosis at 40 mg daily dosage by oral admin-
istration. As no other SERMs have shown such clinical 
efficacies in endometriosis, SR-16234 may be the first 
SERM with reported effi cacy for this disease condition. 
The mechanism action of SR-16234 for endometriosis 
is not well clarifi ed. Other SERMs have some levels of 
partial agonistic activity to ERα and that may be the 
reason for resistance occurring in treatment for breast 
cancer and could be effective in increasing bone mineral 
density in osteoporosis patients. Compared with 1st or 
2nd generation SERMs including tamoxifene, raloxifene 
or baldoxifene, SR-16234 seems to be a purer ERα an-
tagonist and that may be one of the reasons it is effective 
for endometriosis related pain. Its strong affi nity to both 
ERα and ERβ might be important. Bulun et al suggest 
that defi cient methylation of the ERβ promotor results 
in pathological overexpression of ERβ in endometriotic 
stromal cells, high levels of ERβ suppress ERα ex-
pression and a high ERβ to ERα ratio in endometriotic 
stromal cells is associated with suppressed progesterone 
receptor and increased cyclooxygenase-2 levels contrib-
uting to progesterone resistance and infl ammation.23 
 As the affinity of SR-16234 to ERβ is 10 to 100 
times stronger than other SERMs that have been used 
for treatment of breast cancer or osteoporosis. In endo-
metriotic tissues where high estrogen content and high 
ERβ expression, SR-16234 may induce ERβ activation 
to inhibit growth of endometriotic tissue, infl ammatory 
cytokines, COXs expression, and ERβ receptor resis-
tance. 
 In terms of efficacy of drugs for pain associated 
with endometriosis, we compared changes in pelvic pain 
score of SR-16234 and dienogest (data for dienogest and 
placebo derived from the CTD of dienogest) (Fig. 4). SR-
16234 had stronger effects than the placebo, but changes 
in pelvic pain VAS was more profound with dienogest, 
suggesting potential utility of SR-16234 in pain manage-
ment of endometriosis. Further large scale and placebo 
compared clinical trials in the future are necessary for 
confi rmation. 
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Fig. 4. Effects of SR-16234 and dienogest on pelvic pain score 
(VAS) in endometriosis patients. Data of dienogest and placebo 
were derived from common technical document (CTD).
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